AnTolRx
Cambridge
About AnTolRx
At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Their proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2016)
- Website: antolrx.com
- Phone: (617)945-8468
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/antolrx-42044 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.